Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Generex Biotechnology Corp. (GNBTQ) Message Board

I suppose you could. But there would be a wide ran

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36568
(Total Views: 281)
Posted On: 10/09/2020 11:23:30 AM
Posted By: Buildit
Re: Creekrat #22377
I suppose you could. But there would be a wide range based on assumptions of very large unknowns. I’ll take a shot and be quick and conservative...

Inflation adjusted original valuation might be 400MM. And put a multiple on that for 10-year data. Maybe 3x is a reasonable stab? $1.2B or $3/sh for the stagnant cancer biz that isn’t generating revs.

Now take CV and your $2.5B revs #. I’d say there would be a probability factor applied to something like that. I’ll throw out 20% for discussion purposes. That’s 500MM in revs or $1.25/sh.

Growth prospects, could expect a good P/S ratio? I own ZTS... not a perfect proxy by any stretch, but related in some ways. Has a 12.3 P/S. Where Pfizer is a little over 4.

So if we say a lower one than ZTS due to the unknown but more than a behemoth like PFE, maybe 7-8 conservatively? So at a 7.5 P/S, that would be $9.38.

Add back the $3 from above, and you’ve got $12.38, plus some value for other potentials maybe.

But obviously that relies heavily on the CV rev potential for now. If that becomes more likely, the number goes up drastically. If it becomes less likely, a steep dropoff.

Fun exercise to show the potential is there. How much of that would be used in a professional valuation is anyone’s guess... but certainly there’s a pathway for the $4 we need for a listing. And that’s the real key, IMO.

Anyone else?


(3)
(0)




Generex Biotechnology Corp. (GNBTQ) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us